Browse > Article
http://dx.doi.org/10.5483/BMBRep.2018.51.1.227

New insight into transglutaminase 2 and link to neurodegenerative diseases  

Min, Boram (Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University)
Chung, Kwang Chul (Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University)
Publication Information
BMB Reports / v.51, no.1, 2018 , pp. 5-13 More about this Journal
Abstract
Formation of toxic protein aggregates is a common feature and mainly contributes to the pathogenesis of neurodegenerative diseases (NDDs), which include amyotrophic lateral sclerosis (ALS), Alzheimer's, Parkinson's, Huntington's, and prion diseases. The transglutaminase 2 (TG2) gene encodes a multifunctional enzyme, displaying four types of activity, such as transamidation, GTPase, protein disulfide isomerase, and protein kinase activities. Many studies demonstrated that the calcium-dependent transamidation activity of TG2 affects the formation of insoluble and toxic amyloid aggregates that mainly consisted of NDD-related proteins. So far, many important and NDD-related substrates of TG2 have been identified, including $amlyoid-{\beta}$, tau, ${\alpha}-synuclein$, mutant huntingtin, and ALS-linked trans-activation response (TAR) DNA-binding protein 43. Recently, the formation of toxic inclusions mediated by several TG2 substrates were efficiently inhibited by TG2 inhibitors. Therefore, the development of highly specific TG2 inhibitors would be an important tool in alleviating the progression of TG2-related brain disorders. In this review, the authors discuss recent advances in TG2 biochemistry, several mechanisms of molecular regulation and pleotropic signaling functions, and the presumed role of TG2 in the progression of many NDDs.
Keywords
Alzheimer's disease; Cross-linking activity; Huntington's disease; Neurodegenerative diseases; Parkinson's disease; Protein aggregates; Transglutaminase 2;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Gentile V, Davies PJ and Baldini A (1994) The human tissue transglutaminase gene maps on chromosome 20q12 by in situ fluorescence hybridization. Genomics 20, 295-297   DOI
2 Fesus L and Piacentini M (2002) Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 27, 534-539   DOI
3 Fraij BM and Gonzales RA (1997) Organization and structure of the human tissue transglutaminase gene. Biochim Biophys Acta 1354, 65-71   DOI
4 Kiraly R, Demeny M and Fesus L (2011) Protein transamidation by transglutaminase 2 in cells: a disputed Ca2+-dependent action of a multifunctional protein. FEBS J 278, 4717-4739   DOI
5 Shrestha R, Tatsukawa H, Shrestha R et al (2015) Molecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cells. Cell Death Dis 6, e2002   DOI
6 Murthy SN, Iismaa S, Begg G, Freymann DM, Graham RM and Lorand L (2002) Conserved tryptophan in the core domain of transglutaminase is essential for catalytic activity. Proc Natl Acad Sci U S A 99, 2738-2742   DOI
7 Lee KN, Arnold SA, Birckbichler PJ et al (1993) Sitedirected mutagenesis of human tissue transglutaminase: Cys-277 is essential for transglutaminase activity but not for GTPase activity. Biochim Biophys Acta 1202, 1-6   DOI
8 Yee VC, Le Trong I, Bishop PD, Pedersen LC, Stenkamp RE and Teller DC (1996) Structure and function studies of factor XIIIa by x-ray crystallography. Semin Thromb Hemost 22, 377-384   DOI
9 Pinkas DM, Strop P, Brunger AT and Khosla C (2007) Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol 5, e327   DOI
10 Kuo TF, Tatsukawa H and Kojima S (2011) New insights into the functions and localization of nuclear transglutaminase 2. FEBS J 278, 4756-4767   DOI
11 Stamnaes J, Pinkas DM, Fleckenstein B, Khosla C and Sollid LM (2010) Redox regulation of transglutaminase 2 activity. J Biol Chem 285, 25402-25409   DOI
12 Milakovic T, Tucholski J, McCoy E and Johnson GV (2004) Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death. J Biol Chem 279, 8715-8722   DOI
13 Malorni W, Farrace MG, Matarrese P et al (2009) The adenine nucleotide translocator 1 acts as a type 2 transglutaminase substrate: implications for mitochondrialdependent apoptosis. Cell Death Differ 16, 1480-1492   DOI
14 Stephens P, Grenard P, Aeschlimann P et al (2004) Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses. J Cell Sci 117, 3389-3403   DOI
15 Mhaouty-Kodja S (2004) Ghalpha/tissue transglutaminase 2: an emerging G protein in signal transduction. Biol Cell 96, 363-367   DOI
16 Dupuis M, Levy A and Mhaouty-Kodja S (2004) Functional coupling of rat myometrial alpha 1-adrenergic receptors to Gh alpha/tissue transglutaminase 2 during pregnancy. J Biol Chem 279, 19257-19263   DOI
17 DiRaimondo TR, Plugis NM, Jin X and Khosla C (2013) Selective inhibition of extracellular thioredoxin by asymmetric disulfides. J Med Chem 56, 1301-1310   DOI
18 Shin DM, Jeon JH, Kim CW et al (2008) TGFbeta mediates activation of transglutaminase 2 in response to oxidative stress that leads to protein aggregation. FASEB J 22, 2498-2507   DOI
19 Begg GE, Holman SR, Stokes PH, Matthews JM, Graham RM and Iismaa SE (2006) Mutation of a critical arginine in the GTP-binding site of transglutaminase 2 disinhibits intracellular cross-linking activity. J Biol Chem 281, 12603-12609   DOI
20 Gibrat C, Bousquet M, Saint-Pierre M et al (2010) Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor. Prog Neuropsychopharmacol Biol Psychiatry 34, 193-203   DOI
21 Tremblay ME, Saint-Pierre M, Bourhis E, Levesque D, Rouillard C and Cicchetti F (2006) Neuroprotective effects of cystamine in aged parkinsonian mice. Neurobiol Aging 27, 862-870   DOI
22 Davies SW, Turmaine M, Cozens BA et al (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548   DOI
23 Zainelli GM, Ross CA, Troncoso JC, Fitzgerald JK and Mumna NA (2004) Calmodulin regulates transglutaminase 2 cross-linking of huntingtin. J Neurosci 24, 1954-1961   DOI
24 Mastroberardino PG, Iannicola C, Nardacci R et al (2002) 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ 9, 873-880   DOI
25 Bailey CD and Johnson GV (2005) Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregateindependent mechanisms. J Neurochem 92, 83-92   DOI
26 Sun L, Xu S, Zhou M, Wang C, Wu Y and Chan P (2010) Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice. Brain Res 1335, 74-82   DOI
27 Fabbi M, Marimpietri D, Martini S et al (1999) Tissue transglutaminase is a caspase substrate during apoptosis. Cleavage causes loss of transamidating function and is a biochemical marker of caspase 3 activation. Cell Death Differ. 6, 992-1001   DOI
28 Min B, Park H, Lee S et al (2016) CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer. Oncogene 35, 3718-3728   DOI
29 Luciani A, Villella VR, Vasaturo A et al (2009) SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation. J Immunol 183, 2775-2784   DOI
30 Ku BM, Kim DS, Kim KH et al (2013) Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma. FASEB J 27, 3487-3495   DOI
31 Norlund MA, Lee JM, Zainelli GM and Muma NA (1999) Elevated transglutaminase-induced bonds in PHF tau in Alzheimer's disease. Brain Res 851, 154-163   DOI
32 Johnson GV, Cox TM, Lockhart JP, Zinnerman MD, Miller ML and Powers RE (1997) Transglutaminase activity is increased in Alzheimer's disease brain. Brain Res 751, 323-329   DOI
33 Shinagawa R, Masuda S, Sasaki R, Ikura K and Takahata K (1997) In vitro neurotoxicity of amyloid beta-peptide cross-linked by transglutaminase. Cytotechnology 23, 77-85   DOI
34 Curro M, Ferlazzo N, Condello S, Caccamo D and Lentile R (2010) Transglutaminase 2 silencing reduced the beta-amyloid-effects on the activation of human THP-1 cells. Amino Acids 39, 1427-1433   DOI
35 Hartley DM, Zhao C, Speier AC et al (2008) Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiation. J Biol Chem 283, 16790-16800   DOI
36 Boros S, Kamps B, Wunderink L, de Bruijn W, de Jong WW and Boelens WC (2004) Transglutaminase catalyzes differential crosslinking of small heat shock proteins and amyloid-beta. FEBS Lett 576, 57-62   DOI
37 Wang X, Sarkar A, Cicchetti F et al (2005) Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J Neurol Sci 231, 57-66   DOI
38 Sung K, Kamiya N, Kawata N, Kamiya S and Goto M (2010) Functional glass surface displaying a glutamyl donor substrate for transglutaminase-mediated protein immobilization. Biotechnol J 5, 456-462   DOI
39 Karpuj MV, Becher MW, Springer JE et al (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8, 143-149   DOI
40 Dedeoglu A, Kubilus JK, Jeitner TM et al (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22, 8942-8950   DOI
41 Case A, Ni J, Yeh LA and Stein RL (2005) Development of a mechanism-based assay for tissue transglutaminase--results of a high-throughput screen and discovery of inhibitors. Anal Biochem 338, 237-244   DOI
42 Zhang W, Johnson BR and Bjornsson TD (1997) Pharmacologic inhibition of transglutaminase-induced cross-linking of Alzheimer's amyloid beta-peptide. Life Sci 60, 2323-2332   DOI
43 Zemaitaitis MO, Lee JM, Troncoso JC and Muma NA (2000) Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy. J Neuropathol Exp Neurol 59, 983-989   DOI
44 Tucholski J, Kuret J and Johnson GV (1999) Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination. J Neurochem 73, 1871-1880
45 Halverson RA, Lewis J, Frausto S, Hutton M and Muma NA (2005) Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice. J Neurosci 25, 1226-1233   DOI
46 Lin MK and Farrer MJ (2014) Genetics and genomics of Parkinson's disease. Genome Med 6, 48   DOI
47 Kalia LV and Lang AE (2015) Parkinson's disease. Lancet 386, 896-912   DOI
48 de Jager M, van der Wildt B, Schul E et al (2013) Tissue transglutaminase colocalizes with extracellular matrix proteins in cerebral amyloid angiopathy. Neurobiol Aging 34, 1159-1169   DOI
49 Wilhelmus MM, Verhaar R, Andringa G et al (2011) Presence of tissue transglutaminase in granular endoplasmic reticulum is characteristic of melanized neurons in Parkinson's disease brain. Brain Pathol 21, 130-139   DOI
50 Mehta K (2005) Mammalian transglutaminases: a family portrait. Prog Exp Tumor Res 38, 1-18
51 Chai C and Lim KL (2013) Genetic insights into sporadic Parkinson's disease pathogenesis. Curr Genomics 14, 486-501
52 Beck KE, De Girolamo LA, Griffin M and Billett EE (2006) The role of tissue transglutaminase in 1-methyl-4-phenylpyridinium (MPP+)-induced toxicity in differentiated human SH-SY5Y neuroblastoma cells. Neurosci Lett 405, 46-51   DOI
53 Verhaar R, Jongenelen CA, Gerard M et al (2011) Blockade of enzyme activity inhibits tissue transglutaminasemediated transamidation of alpha-synuclein in a cellular model of Parkinson's disease. Neurochem Int 58, 785-793   DOI
54 Junn E, Ronchetti RD, Quezado MM, Kim SY and Mouradian MM (2003) Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 100, 2047-2052   DOI
55 Schmid AW, Chiappe D, Pignat V et al (2009) Dissecting the mechanisms of tissue transglutaminase-induced crosslinking of alpha-synuclein: implications for the pathogenesis of Parkinson disease. J Biol Chem 284, 13128-13142   DOI
56 Sato H, Arawaka S, Hara S et al (2011) Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci 31, 16884-16894   DOI
57 Min B, Kwon YC, Choe KM and Chung KC (2015) PINK1 phosphorylates transglutaminase 2 and blocks its proteasomal degradation. J Neurosci Res 93, 722-735   DOI
58 Grenard P, Bates MK and Aeschlimann D (2001) Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z. J Biol Chem 276, 33066-33078   DOI
59 Park D, Choi SS and Ha KS (2010) Transglutaminase 2: a multi-functional protein in multiple subcellular compartments. Amino Acids 39, 619-631   DOI
60 Sarkar NK, Clarke DD and Waelsch H (1957) An enzymically catalyzed incorporation of amines into proteins. Biochim Biophys Acta 25, 451-452   DOI
61 Achyuthan KE and Greenberg CS (1987) Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. J Biol Chem 262, 1901-1906
62 Nakaoka H, Perez DM, Baek KJ et al (1994) Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science 264, 1593-1596   DOI
63 Hasegawa G, Suwa M, Ichikawa Y et al (2003) A novel function of tissue-type transglutaminase: protein disulphide isomerase. Biochem J 373, 793-803   DOI
64 Jones RA, Nicholas B, Mian S, Davies PJ and Griffin M (1997) Reduced expression of tissue transglutaminase in a human endothelial cell line leads to changes in cell spreading, cell adhesion and reduced polymerisation of fibronectin. J Cell Sci 110, 2461-2472
65 Mishra S and Murphy LJ (2006) The p53 oncoprotein is a substrate for tissue transglutaminase kinase activity. Biochem Biophys Res Commun 339, 726-730   DOI
66 Takeuchi Y, Ohashi H, Birckbichler PJ and Ikejima T (1998) Nuclear translocation of tissue type transglutaminase during sphingosine-induced cell death: a novel aspect of the enzyme with DNA hydrolytic activity. Z Naturforsch C 53, 352-358
67 Verhaar R, Drukarch B, Bol JG, Jongenelen CA, Musters RJ and Wilhelmus MM (2012) Increase in endoplasmic reticulum-associated tissue transglutaminase and enzymatic activation in a cellular model of Parkinson's disease. Neurobiol Dis 45, 839-850   DOI
68 Forno LS (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55, 259-272   DOI
69 Mishra S and Murphy LJ (2004) Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem 279, 23863-23868   DOI
70 Lorand L and Graham RM (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4, 140-156   DOI
71 Nurminskaya MV and Belkin AM (2012) Cellular functions of tissue transglutaminase. Int Rev Cell Mol Biol 294, 1-97
72 Esposito C and Caputo I (2005) Mammalian transglutaminases. Identification of substrates as a key to physiological function and physiopathological relevance. FEBS J 272, 615-631   DOI
73 Lesort M, Tucholski J, Miller ML and Johnson GV (2000) Tissue transglutaminase: a possible role in neurodegenerative diseases. Prog Neurobiol 61, 439-463   DOI
74 Dieterich W, Ehnis T, Bauer M et al (1997) Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 3, 797-801   DOI
75 Sollid LM, Molberg O, McAdam S and Lundin KE (1997) Autoantibodies in coeliac disease: tissue transglutaminase--guilt by association? Gut 41, 851-852   DOI
76 Birckbichler PJ, Orr GR, Conway E and Patterson MK (1977) Transglutaminase activity in normal and transformed cells. Cancer Res 37, 1340-1344
77 Griffin M, Smith LL and Wynne J (1979) Changes in transglutaminase activity in an experimental model of pulmonary fibrosis induced by paraquat. Br J Exp Pathol 60, 653-661